Assembly Biosciences
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Two Tower Pl Fl 7, South San Francisco, ...Phone Number
(833) 509-4583Website
www.assemblybio.comRevenue
$71.1 MillionStock Symbol
ASMBIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Assembly Biosciences
Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States.Explore more
Assembly Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Assembly Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Assembly Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Assembly Biosciences is spiking on competitors!
Funding: Get notified immidiatlly once Assembly Biosciences has new funding data
Click to see if Assembly Biosciences had a recent Job posting/layoffs
Earning: See what the market has to say on Assembly Biosciences recently announced quarterly report
Product Launch: Get notified when Assembly Biosciences launches new products
Congratulate Masked Content for being promoted to Masked Content at Assembly Biosciences
Website visits: Recent activity has been detected on your website
Check if Assembly Biosciences has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined Assembly Biosciences as Masked Content
Find more new buyers
Compare Similar Companies to Assembly Biosciences
Compare insights from companies similar to Assembly Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Assembly Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Assembly Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Assembly Biosciences.
Assembly Biosciences financials insights
Gather financial insights about Assembly Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Multiple Rounds
$20.8M
2024
Private Equity
$12.6M
Private Equity
$30M
Assembly Biosciences Tech Stack
A closer look at the technologies used by Assembly Biosciences
See more technologies
Most Recent Scoops
Project
Assembly Biosciences has presented Phase I-A data for ABI-6250 at EASL, demonstrating a 3- to 4-day half-life supporting once-daily oral dosing, pharmacodynamic bile acid elevations meeting or exceeding those observed with approved doses of bulevirtide, and a favorable safety profile over 10 days of dosing with no adverse events of pruritus.
Medical Research, Pharmaceuticals
Project
Assembly Biosciences has reported phase I-B data for ABI-5366 and ABI-1179, both oral small molecule once-weekly candidates, demonstrating high potential for superior efficacy relative to VALTREX, with ABI-5366 also showing potential for monthly dosing due to its long half-life.
Medical Research, Pharmaceuticals
Project
Assembly Biosciences has highlighted that ABI-6250 targets the recycling of bile acids, which accounts for 75% to 95% of total bile acid load in the body, and anticipates this mechanism may yield improved biochemical outcomes relative to PPAR agonists.
Medical Research
Project
anticipates that ABI-6250, by preventing bile acid entry into the liver, may reduce intrahepatic bile acid levels and IL-31, potentially resulting in lower levels of pruritus or at minimum a neutral effect on itch in patients with cholestatic liver disease.
Project
Clinical Operations
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Assembly Biosciences
Sign Up For FreeTo access detailed company insights
Assembly Biosciences, Inc., a clinical stage biotechnology company, develops oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics to restore health to a dysbiotic microbiome in the United States.... Read More
